186 related articles for article (PubMed ID: 11948106)
1. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol.
Corey E; Quinn JE; Emond MJ; Buhler KR; Brown LG; Vessella RL
Clin Cancer Res; 2002 Apr; 8(4):1003-7. PubMed ID: 11948106
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
3. LuCaP 35: a new model of prostate cancer progression to androgen independence.
Corey E; Quinn JE; Buhler KR; Nelson PS; Macoska JA; True LD; Vessella RL
Prostate; 2003 Jun; 55(4):239-46. PubMed ID: 12712403
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
5. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells.
Gery S; Sawyers CL; Agus DB; Said JW; Koeffler HP
Oncogene; 2002 Jul; 21(31):4739-46. PubMed ID: 12101412
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
Rocchi P; Muracciole X; Fina F; Mulholland DJ; Karsenty G; Palmari J; Ouafik L; Bladou F; Martin PM
Oncogene; 2004 Dec; 23(56):9111-9. PubMed ID: 15489889
[TBL] [Abstract][Full Text] [Related]
7. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
[TBL] [Abstract][Full Text] [Related]
8. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
9. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
10. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
[TBL] [Abstract][Full Text] [Related]
11. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
12. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
15. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer.
Patel BJ; Pantuck AJ; Zisman A; Tsui KH; Paik SH; Caliliw R; Sheriff S; Wu L; deKernion JB; Tso CL; Belldegrun AS
J Urol; 2000 Oct; 164(4):1420-5. PubMed ID: 10992426
[TBL] [Abstract][Full Text] [Related]
16. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
[TBL] [Abstract][Full Text] [Related]
18. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation.
Zou Z; Zhang W; Young D; Gleave MG; Rennie P; Connell T; Connelly R; Moul J; Srivastava S; Sesterhenn I
Clin Cancer Res; 2002 May; 8(5):1172-7. PubMed ID: 12006534
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.
Kyprianou N; English HF; Isaacs JT
Cancer Res; 1990 Jun; 50(12):3748-53. PubMed ID: 2340521
[TBL] [Abstract][Full Text] [Related]
20. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
